Ketorolaco Trometamol Normon (Ketorolac Trometamol)

Ketorolac trometamol inhibits both COX‑1 and COX‑2 enzymes, reducing the synthesis of prostaglandins that mediate inflammation and pain. Lower prostaglandin levels decrease peripheral sensitisation of nociceptors, resulting in analgesic and anti‑inflammatory effects.

The specific dose and frequency are determined by the prescribing clinician based on the patient’s condition, weight, renal function, and overall risk profile. Standard dosing regimens are outlined in clinical guidelines, but the prescriber tailors therapy to each individual.

Safety data for ketorolac during pregnancy and lactation are limited, and the drug is generally avoided, especially in the third trimester, because of potential fetal and neonatal risks. Breastfeeding mothers should consult a healthcare professional before use.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Ketorolac provides potent analgesia comparable to moderate‑dose opioids but without the risk of respiratory depression. Compared with other NSAIDs such as ibuprofen, it has a faster onset and higher potency for short‑term use, though it carries a higher risk of renal and gastrointestinal adverse effects if used beyond recommended durations.

The product should be stored at ambient temperature, preferably below 25 °C, in its original packaging to protect from light and moisture. Vials must be kept upright, and any unused solution should be discarded according to local regulations after the recommended in‑use period.

Ketorolaco Trometamol is administered by a healthcare professional either as an intramuscular injection or an intravenous infusion. The route, rate, and volume are selected by the prescriber to achieve rapid analgesia while monitoring the patient for any adverse reactions.

Serious risks include gastrointestinal ulceration or bleeding, acute renal failure, severe hypersensitivity reactions (including anaphylaxis), and cardiovascular events such as myocardial infarction or stroke. Patients should be monitored closely for signs of these complications, especially when used at higher doses or for longer than recommended.

Ketorolaco Trometamol is contraindicated in patients with known hypersensitivity to ketorolac or other NSAIDs, active peptic ulcer disease, severe renal impairment, uncontrolled hypertension, and those with a history of cardiovascular thrombotic events. It should also be avoided in patients receiving anticoagulant therapy unless specifically directed by a physician.